Logo image of ADMS

Adamas Pharmaceuticals Inc (ADMS) Stock Fundamental Analysis

USA - NASDAQ:ADMS - Common Stock

8.22
+0.06 (+0.74%)
Last: 11/23/2021, 4:18:38 PM
8.3
+0.08 (+0.97%)
After Hours: 11/23/2021, 4:18:38 PM
Fundamental Rating

2

Taking everything into account, ADMS scores 2 out of 10 in our fundamental rating. ADMS was compared to 534 industry peers in the Biotechnology industry. ADMS has a bad profitability rating. Also its financial health evaluation is rather negative. ADMS is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ADMS has reported negative net income.
ADMS Yearly Net Income VS EBIT VS OCF VS FCFADMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 -20M -40M -60M -80M -100M

1.2 Ratios

Industry RankSector Rank
ROA -43.55%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADMS Yearly ROA, ROE, ROICADMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 2K 4K 6K 8K 10K

1.3 Margins

Industry RankSector Rank
OM -44.55%
PM (TTM) -71.1%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADMS Yearly Profit, Operating, Gross MarginsADMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 -5K -10K -15K

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for ADMS has been increased compared to 1 year ago.
Compared to 1 year ago, ADMS has a worse debt to assets ratio.
ADMS Yearly Shares OutstandingADMS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 5M 10M 15M 20M 25M
ADMS Yearly Total Debt VS Total AssetsADMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -3.57, we must say that ADMS is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of -5.76 indicates that ADMS is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -5.76
Debt/FCF N/A
Altman-Z -3.57
ROIC/WACCN/A
WACCN/A
ADMS Yearly LT Debt VS Equity VS FCFADMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 50M -50M 100M -100M

2.3 Liquidity

ADMS has a Current Ratio of 4.53. This indicates that ADMS is financially healthy and has no problem in meeting its short term obligations.
ADMS has a Quick Ratio of 4.17. This indicates that ADMS is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.53
Quick Ratio 4.17
ADMS Yearly Current Assets VS Current LiabilitesADMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 50M 100M 150M 200M

More info and screens

7

3. Growth

3.1 Past

ADMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.84%, which is quite impressive.
Looking at the last year, ADMS shows a very strong growth in Revenue. The Revenue has grown by 26.34%.
ADMS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 107.84% yearly.
EPS 1Y (TTM)46.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.87%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y407.4%
Revenue growth 5Y107.84%
Sales Q2Q%28.33%

3.2 Future

The Earnings Per Share is expected to grow by 12.28% on average over the next years. This is quite good.
The Revenue is expected to grow by 20.86% on average over the next years. This is a very strong growth
EPS Next Y48.66%
EPS Next 2Y34.88%
EPS Next 3Y24.11%
EPS Next 5Y12.28%
Revenue Next Year26.58%
Revenue Next 2Y29.99%
Revenue Next 3Y21.96%
Revenue Next 5Y20.86%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADMS Yearly Revenue VS EstimatesADMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ADMS Yearly EPS VS EstimatesADMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADMS. In the last year negative earnings were reported.
Also next year ADMS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADMS Price Earnings VS Forward Price EarningsADMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -10.88
ADMS Per share dataADMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

ADMS's earnings are expected to grow with 24.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.88%
EPS Next 3Y24.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADMS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Adamas Pharmaceuticals Inc

NASDAQ:ADMS (11/23/2021, 4:18:38 PM)

After market: 8.3 +0.08 (+0.97%)

8.22

+0.06 (+0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)03-01 2022-03-01/amc
Inst Owners0.22%
Inst Owner Change0%
Ins Owners4.9%
Ins Owner Change0%
Market Cap374.98M
Revenue(TTM)88.19M
Net Income(TTM)-62702000
Analysts71.43
Price Target8.69 (5.72%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.25
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -10.88
EPS(TTM)-2.02
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.93
BVpS-0.47
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.55%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -44.55%
PM (TTM) -71.1%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity -5.76
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.53
Quick Ratio 4.17
Altman-Z -3.57
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.87%
EPS Next Y48.66%
EPS Next 2Y34.88%
EPS Next 3Y24.11%
EPS Next 5Y12.28%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y407.4%
Revenue growth 5Y107.84%
Sales Q2Q%28.33%
Revenue Next Year26.58%
Revenue Next 2Y29.99%
Revenue Next 3Y21.96%
Revenue Next 5Y20.86%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Adamas Pharmaceuticals Inc / ADMS FAQ

What is the fundamental rating for ADMS stock?

ChartMill assigns a fundamental rating of 4 / 10 to ADMS.


What is the valuation status of Adamas Pharmaceuticals Inc (ADMS) stock?

ChartMill assigns a valuation rating of 0 / 10 to Adamas Pharmaceuticals Inc (ADMS). This can be considered as Overvalued.


What is the profitability of ADMS stock?

Adamas Pharmaceuticals Inc (ADMS) has a profitability rating of 3 / 10.


How financially healthy is Adamas Pharmaceuticals Inc?

The financial health rating of Adamas Pharmaceuticals Inc (ADMS) is 4 / 10.